Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial - Poll - MDSpire

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • By

  • Jinhong Zhu

  • Jinfeng Zhang

  • Xiaodong Ling

  • Changhong Wang

  • Yingnan Yang

  • Yangzhong Xin

  • Hao Jiang

  • Hao Liang

  • Luquan Zhang

  • Xionghai Qin

  • Jingle Lei

  • Chengyuan Fang

  • Xinxin Yang

  • Yuning Wang

  • Wei Meng

  • Xiaoyuan Wang

  • Hongxue Meng

  • Jianqun Ma

  • December 28, 2025

  • 0 min

Share

Original Source(s)

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • by Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma

  • December 28, 2025

Related Content

Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma

Dose-dependent tuning of HSP70–Beclin-1 by kaempferol governs autophagy and chemosensitivity

Exploring the Role of the ITGβ1-CLIC1 Pathway in the Progression and Immune Evasion of Oral Squamous Cell Carcinoma: Findings from a Tumor-Mimetic Extracellular Matrix Model